{
  "event_id": "8619c6755dca",
  "ticker": "VRTX",
  "company_name": "Vertex Pharmaceuticals",
  "drug_name": "TRIKAFTA",
  "pdufa_date": "20250925",
  "approval_type": {
    "status": "found",
    "value": "nda",
    "source": "websearch:VX-445-102 Phase 3 (Approved Oct 2019)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:05:55.358304",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Cystic fibrosis (F508del)",
    "source": "websearch:VX-445-102 Phase 3 (Approved Oct 2019)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:05:55.358306",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "elexacaftor/tezacaftor/ivacaftor",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:39:43.834535",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Respiratory",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:59.180261",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:39:43.834535",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:VX-445-102 Phase 3 (Approved Oct 2019)",
    "confidence": 0.95,
    "evidence": [
      "VX-445-102 Phase 3 (Approved Oct 2019)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:05:55.358292",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "<0.001",
    "source": "websearch:VX-445-102 Phase 3 (Approved Oct 2019)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:05:55.358298",
    "error": null
  },
  "p_value_numeric": 0.001,
  "effect_size": {
    "status": "found",
    "value": "14.3 ppFEV1 improvement",
    "source": "websearch:VX-445-102 Phase 3 (Approved Oct 2019)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T19:05:55.358301",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "iPS Cell Response to CFTR Modulators: Study of Trikafta in CF Patients Carrying Partial Function Mutations or N1303K CFTR",
    "A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)",
    "A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)",
    "Long-term Effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on Exertional Symptoms, Exercise Performance, Ventilatory Responses, and Body Composition in Adults With Cystic Fibrosis",
    "A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation"
  ],
  "nct_ids": [
    "NCT03506061",
    "NCT03525444",
    "NCT03525548",
    "NCT05279040",
    "NCT05274269"
  ],
  "enrollment": {
    "count": 405,
    "type": "ACTUAL",
    "nct_id": "NCT03525444",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:31:41.576694"
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:29:14.117684",
  "enriched_at": "2026-01-11T20:40:08.312894",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "32c81778cf93",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": false
  },
  "mechanism_of_action": "CFTR modulator",
  "adcom_info": {
    "scheduled": true,
    "held": true,
    "outcome": "favorable",
    "vote": "positive"
  },
  "days_to_pdufa": -107,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:42.770394",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:47:15.114198"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:47:15.114206"
  },
  "breakthrough_therapy": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "When did Trikafta come out? A guide to its FDA approval timeline"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:39:57.237515",
    "search_status": "FOUND"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "2023 Affordability Review Summary Report: Trikafta"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:40:00.584111",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "FDA approves new breakthrough therapy for cystic fibrosis"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:40:01.642980",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Trikafta approved in CF for 94 more CFTR gene mutations When Was Trikafta Approved in the US? An FDA"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:40:02.919492",
    "search_status": "FOUND"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:40:08.312868",
    "search_status": "CONFIRMED_NONE"
  }
}